---
title: "Immunic (IMUX) news: reverse split, going concern and offering"
url: "https://aibio.space/companies/immunic/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "IMUX reverse split, going concern, offering and Nasdaq notice news: Immunic gets extra 180 days on Nasdaq bid price rule after transfer to Capital Market."
---

IMUX Immunic, Inc. NASDAQ · United States

# Immunic (IMUX) news IMUX reverse split, going concern and offering news

Listings · 2026-01-06

## [Immunic gets extra 180 days on Nasdaq bid price rule after transfer to Capital Market](https://aibio.space/news/immunic-gets-extra-180-days-nasdaq-bid-price-rule-after-transfer/)

Nasdaq approved Immunic's move from the Global Select Market to the Capital Market, with trading there from January 7, 2026. The company now has until June 22, 2026 to regain compliance with the $1.00 minimum bid price and has told Nasdaq it would seek a reverse stock split if necessary.

## Latest Immunic news

1. 2025-06-27 Listings [Immunic gets Nasdaq notice after stock falls below $1.00 for 30 days](https://aibio.space/news/immunic-gets-nasdaq-notice-after-stock-falls-below-1-00-30-days/) The company has until December 24, 2025 to regain compliance. The notice has no immediate effect on its listing on The Nasdaq Global Select Market.
2. 2025-05-28 Financings [Immunic launches pre-funded warrant offering; final terms total $64,991,334](https://aibio.space/news/immunic-launches-pre-funded-warrant-offering-final-terms-total-64-991/) Immunic began an underwritten warrant offering on May 28, 2025 and set final terms on May 30: $0.7499 a unit, $64,991,334 in total. Leerink Partners is sole bookrunner.
3. 2025-04-09 Financings [Immunic, Inc. prices $5.1 million registered direct offering at $0.90 per share](https://aibio.space/news/immunic-inc-prices-5-1-million-registered-direct-offering-0-90-share/) Immunic agreed on April 9, 2025 to sell 5,666,667 shares at $0.90 each for about $5.1 million, with Titan Partners Group LLC as sole placement agent. The company's 2024 annual report carried a going concern doubt and reported $35.7 million in cash at year end.

## Immunic at a glance

- **Ticker**: IMUX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $155.1 million

### Related companies

- [Windtree Therapeutics](https://aibio.space/companies/windtree-therapeutics/) OTC: WINT
- [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP
- [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN
- [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) NASDAQ: RARE
- [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) OTC: AOXG
- [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) NASDAQ: GYRE
- [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) NASDAQ: LENZ
- [BeyondSpring](https://aibio.space/companies/beyondspring/) NASDAQ: BYSI

### Also on NASDAQ

- [Inhibrx Biosciences](https://aibio.space/companies/inhibrx-biosciences/) INBX
- [NATURAL ALTERNATIVES INTERNATIONAL INC](https://aibio.space/companies/natural-alternatives-international/) NAII
- [Precigen](https://aibio.space/companies/precigen/) PGEN
- [Alector](https://aibio.space/companies/alector/) ALEC
- [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) RNAZ
- [Vericel](https://aibio.space/companies/vericel/) VCEL

## Immunic annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$82.0 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) | [$80.0 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) |
| Net income (loss) | [-$97.2 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) | [-$100.5 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) |
| Cash from operations | [-$85.8 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) | [-$84.8 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) |
| Cash and equivalents | [$15.5 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000018/) | [$35.7 million](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $155.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Immunic

Did Immunic do a reverse stock split?

Our latest story on this, dated Jan 6, 2026: "Immunic gets extra 180 days on Nasdaq bid price rule after transfer to Capital Market". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunic-gets-extra-180-days-nasdaq-bid-price-rule-after-transfer/).

Has Immunic issued a going-concern warning?

Our latest story on this, dated Apr 9, 2025: "Immunic, Inc. prices $5.1 million registered direct offering at $0.90 per share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunic-inc-prices-5-1-million-registered-direct-offering-0-90-share/).

Has Immunic raised money recently?

Our latest story on this, dated May 28, 2025: "Immunic launches pre-funded warrant offering; final terms total $64,991,334". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunic-launches-pre-funded-warrant-offering-final-terms-total-64-991/).

Has Immunic received a Nasdaq deficiency notice?

Our latest story on this, dated Jun 27, 2025: "Immunic gets Nasdaq notice after stock falls below $1.00 for 30 days". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunic-gets-nasdaq-notice-after-stock-falls-below-1-00-30-days/).

What is the ticker symbol of Immunic?

Immunic, Inc. trades under the ticker IMUX on NASDAQ.

Where is Immunic listed?

Immunic, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:10V; LS:A428WY; LSX:A428WY.

What is the SEC CIK of Immunic?

The SEC Central Index Key (CIK) for Immunic, Inc. is 1280776. Its filings are on SEC EDGAR.

How many shares does Immunic have outstanding?

13,644,467 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-11.

Which country or territory is Immunic listed under?

Our directory records Immunic, Inc. under United States.

What does Immunic do?

Our directory classifies Immunic, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Immunic?

The ISIN recorded for Immunic, Inc. is US4525EP2001.

Does aibio.space cover Immunic?

aibio.space lists Immunic, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Immunic incorporated?

SEC records list its state or country of incorporation as DE.

Is Immunic profitable?

Immunic, Inc. reported a net loss of $97.2 million for the fiscal year ended Dec 31, 2025, and used $85.8 million of cash in operations, per its annual report to the SEC.

How much does Immunic spend on research and development?

$82.0 million in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: Immunic

Members talk about Immunic (IMUX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Immunic, newest first. Each line links the filing it comes from.

1. 2026-05-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/e665513_ex99-1.htm)
2. 2026-04-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/e665394_ex99-1.htm)
3. 2026-04-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000495/e665386_ex99-1.htm)
4. 2026-04-14 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000461/e665361_8k-immunic.htm)
5. 2026-04-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000382/e665306_ex99-1.htm)
6. 2026-03-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000201/e665189_def14a-immunic.htm)
7. 2026-02-20 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000167/e665172_pre14a-immunic.htm)
8. 2026-02-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex99-1.htm)
9. 2026-01-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000011/e665076_8k-immunic.htm)
10. 2025-06-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000943/e664657_8k-immunic.htm)
11. 2025-05-28 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000730/e664552_ex99-1.htm)
12. 2025-04-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000454/e664373_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IMUX on TradingView](https://www.tradingview.com/symbols/NASDAQ-IMUX/).

## SEC filings and registration

- **SEC name**: Immunic, Inc.

- **CIK**: 1280776

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: IMUX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 1200 AVENUE OF THE AMERICAS, NEW YORK, United States, 10036

- **Phone**: (332) 255-9818

- **Shares outstanding**: 13,644,467 as of 2026-07-31 (10-Q filed 2026-08-11)

- **Former names**: VITAL THERAPIES INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1280776/000119380526001219/e665777_8k-immunic.htm) filed 2026-09-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1280776/000119380526001196/e665768_8k-immunic.htm) filed 2026-09-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_8k-immunic.htm) filed 2026-08-11
- [10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000018/vtl-20260630.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000966/e665650_8k-immunic.htm) filed 2026-07-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000916/e665619_8k-immunic.htm) filed 2026-07-06
- [8-K](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000882/e665616_8k-immunic.htm) filed 2026-06-29
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000719/e665517_def14a-immunic.htm) filed 2026-05-29

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001280776), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Immunic, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMUX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Immunic, Inc.

- **Ticker**: IMUX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US4525EP2001

- **Other listed symbols**: GETTEX:10V; LS:A428WY; LSX:A428WY

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IMUX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/immunic/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immunic (IMUX) news: reverse split, going concern and offering", 2026-10-31, https://aibio.space/companies/immunic/